97 related articles for article (PubMed ID: 8788169)
21. The canine factor VIII 3'-untranslated region and a concatemeric hepatocyte nuclear factor 1 regulatory element enhance factor VIII transgene expression in vivo.
Notley C; Killoran A; Cameron C; Wynd K; Hough C; Lillicrap D
Hum Gene Ther; 2002 Sep; 13(13):1583-93. PubMed ID: 12228013
[TBL] [Abstract][Full Text] [Related]
22. Development and application of a minimal-adenoviral vector system for gene therapy of hemophilia A.
Zhang WW; Josephs SF; Zhou J; Fang X; Alemany R; Balagué C; Dai Y; Ayares D; Prokopenko E; Lou YC; Sethi E; Hubert-Leslie D; Kennedy M; Ruiz L; Rockow-Magnone S
Thromb Haemost; 1999 Aug; 82(2):562-71. PubMed ID: 10605752
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the duration of human factor VIII expression in nonhuman primates after systemic delivery of an adenoviral vector.
Andrews JL; Shirley PS; Iverson WO; Sherer AD; Markovits JE; King L; Lyons RM; Kaleko M; Connelly S
Hum Gene Ther; 2002 Jul; 13(11):1331-6. PubMed ID: 12162815
[TBL] [Abstract][Full Text] [Related]
24. Sustained FVIII expression and phenotypic correction of hemophilia A in neonatal mice using an endothelial-targeted sleeping beauty transposon.
Liu L; Mah C; Fletcher BS
Mol Ther; 2006 May; 13(5):1006-15. PubMed ID: 16464640
[TBL] [Abstract][Full Text] [Related]
25. Sequences within the coding regions of clotting factor VIII and CFTR block transcriptional elongation.
Koeberl DD; Halbert CL; Krumm A; Miller AD
Hum Gene Ther; 1995 Apr; 6(4):469-79. PubMed ID: 7542032
[TBL] [Abstract][Full Text] [Related]
26. Sustained expression of Epstein-Barr virus episomal vector mediated factor VIII in vivo following muscle electroporation.
Mei WH; Qian GX; Zhang XQ; Zhang P; Lu J
Haemophilia; 2006 May; 12(3):271-9. PubMed ID: 16643213
[TBL] [Abstract][Full Text] [Related]
27. Expression of human coagulation factor VIII in adipocytes transduced with the simian immunodeficiency virus agmTYO1-based vector for hemophilia A gene therapy.
Ogata K; Mimuro J; Kikuchi J; Tabata T; Ueda Y; Naito M; Madoiwa S; Takano K; Hasegawa M; Ozawa K; Sakata Y
Gene Ther; 2004 Feb; 11(3):253-9. PubMed ID: 14737084
[TBL] [Abstract][Full Text] [Related]
28. Adenoviral vector-mediated expression of physiologic levels of human factor VIII in nonhuman primates.
Brann T; Kayda D; Lyons RM; Shirley P; Roy S; Kaleko M; Smith T
Hum Gene Ther; 1999 Dec; 10(18):2999-3011. PubMed ID: 10609660
[TBL] [Abstract][Full Text] [Related]
29. Expression of therapeutic levels of factor VIII in hemophilia A mice using a novel adeno/adeno-associated hybrid virus.
Gnatenko DV; Wu Y; Jesty J; Damon AL; Hearing P; Bahou WF
Thromb Haemost; 2004 Aug; 92(2):317-27. PubMed ID: 15269828
[TBL] [Abstract][Full Text] [Related]
30. An induced pluripotent stem cell-mediated and integration-free factor VIII expression system.
Yakura Y; Ishihara C; Kurosaki H; Kazuki Y; Komatsu N; Okada Y; Doi T; Takeya H; Oshimura M
Biochem Biophys Res Commun; 2013 Feb; 431(2):336-41. PubMed ID: 23291180
[TBL] [Abstract][Full Text] [Related]
31. Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer.
Kang Y; Xie L; Tran DT; Stein CS; Hickey M; Davidson BL; McCray PB
Blood; 2005 Sep; 106(5):1552-8. PubMed ID: 15886327
[TBL] [Abstract][Full Text] [Related]
32. Enhanced plasma factor VIII activity in mice via cysteine mutation using dual vectors.
Zhu F; Liu Z; Miao J; Qu H; Chi X
Sci China Life Sci; 2012 Jun; 55(6):521-6. PubMed ID: 22744182
[TBL] [Abstract][Full Text] [Related]
33. Gene therapy for hemophilia A.
Connelly S; Kaleko M
Thromb Haemost; 1997 Jul; 78(1):31-6. PubMed ID: 9198123
[TBL] [Abstract][Full Text] [Related]
34. Partial correction of murine hemophilia A with neo-antigenic murine factor VIII.
Sarkar R; Gao GP; Chirmule N; Tazelaar J; Kazazian HH
Hum Gene Ther; 2000 Apr; 11(6):881-94. PubMed ID: 10779165
[TBL] [Abstract][Full Text] [Related]
35. Long-term persistence of human bone marrow stromal cells transduced with factor VIII-retroviral vectors and transient production of therapeutic levels of human factor VIII in nonmyeloablated immunodeficient mice.
Chuah MK; Van Damme A; Zwinnen H; Goovaerts I; Vanslembrouck V; Collen D; VandenDriessche T
Hum Gene Ther; 2000 Mar; 11(5):729-38. PubMed ID: 10757352
[TBL] [Abstract][Full Text] [Related]
36. [Retroviral-mediated high efficient in vitro expression of human coagulation factor VIII].
Guo X; Wang H; Chu H; Wang X; Qu B; Li Z; Qi Z; Wang Z
Zhonghua Xue Ye Xue Za Zhi; 2000 Sep; 21(9):457-9. PubMed ID: 11877017
[TBL] [Abstract][Full Text] [Related]
37. A factor VIII minigene comprising the truncated intron I of factor IX highly improves the in vitro production of factor VIII.
Plantier JL; Rodriguez MH; Enjolras N; Attali O; Négrier C
Thromb Haemost; 2001 Aug; 86(2):596-603. PubMed ID: 11522009
[TBL] [Abstract][Full Text] [Related]
38. In vivo evaluation of a novel epitope-tagged human factor VIII-encoding adenoviral vector.
Roy S; Shirley PS; Connelly S; Andrews JL; Kayda DB; Gardner JM; Kaleko M
Haemophilia; 1999 Sep; 5(5):340-8. PubMed ID: 10583516
[TBL] [Abstract][Full Text] [Related]
39. Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs.
Gallo-Penn AM; Shirley PS; Andrews JL; Tinlin S; Webster S; Cameron C; Hough C; Notley C; Lillicrap D; Kaleko M; Connelly S
Blood; 2001 Jan; 97(1):107-13. PubMed ID: 11133749
[TBL] [Abstract][Full Text] [Related]
40. [Molecular genetics of hemophilia A].
De Brasi CD; Slavutsky IR; Larripa IB
Medicina (B Aires); 1996; 56(5 Pt 1):509-17. PubMed ID: 9239887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
